- Home
- OCGN vs EBS Comparison
OCGN vs EBS Comparison
Compare OCGN & EBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OCGN | EBS |
|---|---|---|
| Founded | 2013 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 419.8M | 423.6M |
| IPO Year | 2014 | 2006 |
Fundamental Metrics
Financial Performance| Metric | OCGN | EBS |
|---|---|---|
| Price | $1.18 | $7.75 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | $9.75 | ★ $12.00 |
| AVG Volume (30 Days) | ★ 5.0M | 755.4K |
| Earning Date | 05-05-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 31.58 | ★ 125.83 |
| EPS | N/A | ★ 0.07 |
| Revenue | N/A | ★ $742,900,000.00 |
| Revenue This Year | N/A | $1.29 |
| Revenue Next Year | $1,718.38 | N/A |
| P/E Ratio | ★ N/A | $118.43 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.90 | $5.62 |
| 52 Week High | $2.73 | $14.06 |
Technical Indicators
Market Signals| Indicator | OCGN | EBS |
|---|---|---|
| Relative Strength Index (RSI) | 32.74 | 43.72 |
| Support Level | $1.09 | $7.73 |
| Resistance Level | $1.92 | $8.54 |
| Average True Range (ATR) | 0.06 | 0.43 |
| MACD | -0.00 | -0.03 |
| Stochastic Oscillator | 3.70 | 23.91 |
Price Performance
Historical ComparisonAbout OCGN Ocugen Inc.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
About EBS Emergent Biosolutions Inc.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.